SecBot SecBot
SECBOTREPLAY Home › Report › UTHR

UTHR · CEO Martine Rothblatt and EVP Paul Mahon sold a combined $989K in…

UNITED THERAPEUTICS Corp · CLUSTER filed Aug 10, 2026 at 16:38 ET

At the news

NEUTRALIMPACT 2/10

CLUSTER filed Aug 10, 2026 at 16:38 ET

CEO Martine Rothblatt and EVP Paul Mahon sold a combined $989K in open-market shares within two days of United Therapeutics' Q2 2026 earnings, which showed a 2% revenue miss and 4% decline in total Tyvaso sales. While the dollar amount is trivial relative to the $22.7B market cap (0.004%), the timing, immediately after a mixed earnings report, and the CEO's exercise of 9,500 options for cashless net-share settlement suggest the sales are primarily liquidity-driven rather than a bearish signal. The cluster is neutral: the CEO's sales follow a typical post-exercise pattern, and the EVP's sale is modest. No material directional read-through for the stock.

  • CEO Martine Rothblatt sold 632 shares at $539.14, 625 at $538.54, and 2,781 at $531.30 among 14 open-market sales on 2026-08-07, totaling ~$4.6M
  • CEO also exercised 9,500 options at $0 (non-cash) and 9,500 options at $135.42 (cash exercise of $1.29M) on the same day
  • EVP Paul Mahon sold 1,360 shares at $515.93 and 780 shares at $517.94 on 2026-08-06, totaling ~$1.1M
  • Total open-market sales by both insiders: ~$5.7M, or 0.025% of $22.7B market cap

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access